X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Exscientia and the University of Oxford announce partnership to develop treatments for Alzheimer's disease

    Exscientia and the University of Oxford announce partnership to develop treatments for Alzheimer’s disease

    Fasenra shows consistent safety and sustained efficacy in long-term Phase III BORA trial in severe eosinophilic asthma

    AstraZeneca and IDT Biologika sign LOI to increase COVID-19 vaccine manufacturing in Europe and secure long-term supply capacity

    Astrazeneca Says Covid-19 Long-Acting Antibody Combination AZD7442 Rapidly Advances Into Phase III Clinical Trials

    Algernon Pharmaceuticals Considers Adding Lung Scarring as an Additional Endpoint for its Phase 2b/3 COVID-19 Study Protocol

    Samsung Biologics, National OncoVenture, and Eutilex obtains IND Approval from FDA

    Samsung Biologics, National OncoVenture, and Eutilex obtains IND Approval from FDA

    Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral COVID-19 Tablet Vaccine Candidate

    Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral COVID-19 Tablet Vaccine Candidate

    Gavi, the Vaccine Alliance, Collaborates with Salesforce to Help Equitably Distribute Two Billion COVID-19 Vaccines by the End of 2021

    GSK and CureVac to develop next generation mRNA COVID-19 vaccines

    Oxford leads first trial investigating dosing with alternating vaccines

    Oxford leads first trial investigating dosing with alternating vaccines

    Moderna Provides Business Update and Announces Three New Development Programs in Infectious Disease Vaccines

    Moderna Provides Business Update and Announces Three New Development Programs in Infectious Disease Vaccines

    Merck, Pfizer get EU nod for Bavencio as bladder cancer maintenance

    Merck, Pfizer get EU nod for Bavencio as bladder cancer maintenance

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Exscientia and the University of Oxford announce partnership to develop treatments for Alzheimer's disease

    Exscientia and the University of Oxford announce partnership to develop treatments for Alzheimer’s disease

    Fasenra shows consistent safety and sustained efficacy in long-term Phase III BORA trial in severe eosinophilic asthma

    AstraZeneca and IDT Biologika sign LOI to increase COVID-19 vaccine manufacturing in Europe and secure long-term supply capacity

    Astrazeneca Says Covid-19 Long-Acting Antibody Combination AZD7442 Rapidly Advances Into Phase III Clinical Trials

    Algernon Pharmaceuticals Considers Adding Lung Scarring as an Additional Endpoint for its Phase 2b/3 COVID-19 Study Protocol

    Samsung Biologics, National OncoVenture, and Eutilex obtains IND Approval from FDA

    Samsung Biologics, National OncoVenture, and Eutilex obtains IND Approval from FDA

    Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral COVID-19 Tablet Vaccine Candidate

    Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral COVID-19 Tablet Vaccine Candidate

    Gavi, the Vaccine Alliance, Collaborates with Salesforce to Help Equitably Distribute Two Billion COVID-19 Vaccines by the End of 2021

    GSK and CureVac to develop next generation mRNA COVID-19 vaccines

    Oxford leads first trial investigating dosing with alternating vaccines

    Oxford leads first trial investigating dosing with alternating vaccines

    Moderna Provides Business Update and Announces Three New Development Programs in Infectious Disease Vaccines

    Moderna Provides Business Update and Announces Three New Development Programs in Infectious Disease Vaccines

    Merck, Pfizer get EU nod for Bavencio as bladder cancer maintenance

    Merck, Pfizer get EU nod for Bavencio as bladder cancer maintenance

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development

Exscientia and the University of Oxford announce partnership to develop treatments for Alzheimer’s disease

Content Team by Content Team
14th February 2021
in Drug Development, News
Exscientia and the University of Oxford announce partnership to develop treatments for Alzheimer's disease

Exscientia, a leading AI Drug Discovery company, has announced its collaboration with the Alzheimer’s Research UK University of Oxford Drug Discovery Institute (ARUK-ODDI) to develop medicines targeting neuroinflammation for the treatment of Alzheimer’s disease (AD).

AD is the most common form of dementia worldwide, with an estimated 44 million people living with AD or related form of dementia [1,2]. Symptoms of this progressive disease are debilitating, distressing – for both those with the disease and their loved ones –and there is currently no cure [3].

This exciting new partnership unites Exscientia’s AI-driven molecular design capabilities with the deep therapy area knowledge and technical expertise of the ARUK-ODDI.

The collaboration will focus on a specific neuroinflammatory pathway implicated in the development of AD. Activation of the NLRP3 inflammasome has been shown to have an important role in AD pathogenesis and, while there have been other efforts to develop anti-inflammatory drugs for AD [4], targeting NLRP3 inflammasome inhibition in the brain is an innovative therapeutic approach.

Exscientia’s proven AI-driven technology will be applied to efficiently generate high-value novel clinical assets targeting this pathway. Feeding into this are chemical starting points that modulate NLRP3 inflammasome formation identified over years of research by the ARUK-ODDI. Coupling Exscientia’s Centaur Chemist® AI-design systems with the ARUK-ODDI’s biology and screening expertise is expected to speed up delivery of distinct candidate molecules for AD.

Exscientia’s COO David Hallett commented: “Alzheimer’s is a dreadful disease that affects tens of millions worldwide. Despite clinical trials of numerous agents over a wide range of mechanisms, the last new Alzheimer’s medication, was approved nearly two decades ago. Alzheimer’s drug development is costly, complex and extremely challenging with clinical trial failure rate being the highest of any therapeutic area. Our mission is to make novel drugs available to all and we are excited to utilise our AI drug discovery platform and work alongside the expertise of the Alzheimer’s Research UK-Oxford Drug Discovery Institute team to accelerate innovation and develop potential medicines to solve this global epidemic.”

Expanding on this new relationship, Dr John Davis, CSO of the Alzheimer’s Research UK-Oxford Drug Discovery Institute drew attention to the benefits gained from the complementary capabilities of both partners: “We are delighted to be partnering with Exscientia. Their state-of-the-art AI capabilities will enable us to investigate multiple molecules in parallel and accelerate the project towards candidate declaration. Human genetic variation points towards a critical role for the body’s immune system in an individual’s risk of developing Alzheimer’s disease. It is vital that we develop treatments that target neuroinflammatory mechanisms underlying dementia.”

Dr Sara Imarisio, Head of Research at Alzheimer’s Research UK said:
“Scientist’s at our ARUK-Oxford Drug Discovery Institute are ideally placed to capitalise on the latest discoveries and work with partners to help translate this into drugs that could be tested in clinical trials. With nearly one million people in the UK living with dementia, there isn’t a moment to waste.”

About Exscientia

Exscientia is an Artificial Intelligence (AI)-driven pharmatech, committed to discovering medicines in the fastest and most effective manner for patients. As a clinical stage company, Exscientia is the first to progress AI-designed small molecules into a clinical setting, demonstrating the ability of AI to transform the pharmaceutical industry.

Drug design is precision engineering at the molecular scale. To transform the industry, Exscientia has built dedicated AI systems that efficiently learn from the widest range of data and consistently re-apply enhanced knowledge through iterations of design. Because Exscientia’s AI systems learn more rapidly and effectively than human-led efforts, candidate molecules satisfying complex therapeutic requirements are discovered with revolutionary efficiency.

Exscientia puts AI at the centre of its strategy to revolutionise drug discovery, designing therapeutics for areas of high unmet need, that will positively impact patients.

Previous Post

PDA to Collaborate with Deloitte and U.S. FDA to Improve the Quality of Compounded Drugs

Related Posts

PDA to Collaborate with Deloitte and U.S. FDA to Improve the Quality of Compounded Drugs
News

PDA to Collaborate with Deloitte and U.S. FDA to Improve the Quality of Compounded Drugs

14th February 2021
Fasenra shows consistent safety and sustained efficacy in long-term Phase III BORA trial in severe eosinophilic asthma
Drug Development

AstraZeneca and IDT Biologika sign LOI to increase COVID-19 vaccine manufacturing in Europe and secure long-term supply capacity

14th February 2021
Moderna Provides Business Update and Announces Three New Development Programs in Infectious Disease Vaccines
News

Moderna inks agreement to supply of 5 million &10 million doses of Covid-19 vaccine to Taiwan and Colombia governments

14th February 2021
Allergy Alarm Raised On Pfizer-BioNTech COVID-19 Vaccine
Manufacturing

New Zealand approves use of Pfizer-BioNtechs Covid-19 vaccine

14th February 2021
Astrazeneca Says Covid-19 Long-Acting Antibody Combination AZD7442 Rapidly Advances Into Phase III Clinical Trials
Clinical Trials

Algernon Pharmaceuticals Considers Adding Lung Scarring as an Additional Endpoint for its Phase 2b/3 COVID-19 Study Protocol

14th February 2021
Cancer Treatment Can Be Cloned For COVID-19
Manufacturing

Pfizer and IDA Foundation Partner to Expand Access to Essential Cancer Treatments in 70 Low- and Lower-Middle-Income Countries

14th February 2021

Latest News

Exscientia and the University of Oxford announce partnership to develop treatments for Alzheimer's disease
Drug Development

Exscientia and the University of Oxford announce partnership to develop treatments for Alzheimer’s disease

14th February 2021
PDA to Collaborate with Deloitte and U.S. FDA to Improve the Quality of Compounded Drugs
News

PDA to Collaborate with Deloitte and U.S. FDA to Improve the Quality of Compounded Drugs

14th February 2021
Fasenra shows consistent safety and sustained efficacy in long-term Phase III BORA trial in severe eosinophilic asthma
Drug Development

AstraZeneca and IDT Biologika sign LOI to increase COVID-19 vaccine manufacturing in Europe and secure long-term supply capacity

14th February 2021
Moderna Provides Business Update and Announces Three New Development Programs in Infectious Disease Vaccines
News

Moderna inks agreement to supply of 5 million &10 million doses of Covid-19 vaccine to Taiwan and Colombia governments

14th February 2021
Samsung BioLogics
Manufacturing

Samsung Biologics, National OncoVenture, and Eutilex obtains IND Approval from FDA

14th February 2021
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In